Existing data on breast cancer in African-American women

Clarke, Christina A.; West, Dee W.; Edwards, Brenda K.; Ph.D., M.P.H. Larry W. Figgs; Kerner, Jon; Schwartz, Myron

doi:10.1002/cncr.11026

Cited by 29 publications

(16 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In an audit of SEER data, the accuracy of the data was ascertained to be 98%. 31 Based on the these assumptions, systematic errors would most likely have a minimal impact on the conclusions of this study. The majority of lymph node micrometastases are solitary.…”

Section: Discussionmentioning

confidence: 91%

Significance of micrometastases on the survival of women with T1 breast cancer

Maibenco

Dombi

Kau

et al. 2006

Cancer

View full text Add to dashboard Cite

BACKGROUND The most important factor in predicting survival among women with newly diagnosed breast cancer is the status of the axillary lymph nodes. Although straightforward to define, the impact of micrometastases on survival remains to be completely determined. METHODS A review of data from the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute was performed using 43,921 cases diagnosed from January 1988 through December 2001. Among women with invasive breast carcinomas ≤2 cm undergoing a resection of the primary malignancy and an axillary lymph node dissection, there were 42,197 cases without lymph node metastases and 1724 cases with micrometastases. Survival differences among these 2 groups were evaluated and are reported here. RESULTS Survival at 12 years was modestly affected by the presence of either solitary (5.0%) or multiple lymph nodes (3.6%) with micrometastases when compared with lymph node‐negative cases. In subgroup analyses, the decreased survival associated with micrometastases was inconsistent. The most significant survival disadvantage associated with micrometastases was found in cases with Grade 3 carcinomas. CONCLUSIONS The modest and variable impact of micrometastases on long‐term survival indicates that micrometastases are an important, but not a dominant, prognostic indicator. Cancer 2006. © 2006 American Cancer Society.

show abstract

Section: Discussionmentioning

confidence: 91%

Significance of micrometastases on the survival of women with T1 breast cancer

Maibenco

Dombi

Kau

et al. 2006

Cancer

View full text Add to dashboard Cite

show abstract

“…African-American women are more likely to present at a younger age as 33 % of African-Americans were diagnosed at age <50 years compared with 21.9 % of white women [25]. After the Women's Health Initiative reported the link between breast cancer and hormone replacement therapy in a randomized control trial, the subsequent mass cessation of hormone replacement therapy in 2002 is felt to have contributed to a decrease in breast cancer incidence over the next 2 years [26,27].…”

Section: Biology Of Er Subtypes Of Breast Cancermentioning

confidence: 99%

“…For ER tumors, incidence rates decreased 4.7 % for whites but increased 4 % for African-Americans [28], which includes the higher rate of estrogen only therapy among African-Americans and the higher rates of obesity among African-American women. African-American women diagnosed with breast cancer are more likely to die than whites [25].…”

Section: Biology Of Er Subtypes Of Breast Cancermentioning

confidence: 99%

Heat Shock Proteins in Triple-Negative Breast Cancer (TNBC) Treatment

Kaur

Singh

Galukande

et al. 2015

Heat Shock Proteins

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) accounts for approximately 15 % of breast cancer diagnoses, and exhibits substantial overlap with basal-type and BRCA1-positive breast cancer. Large population based studies have identified a higher proportion of triple-negative breast tumors among premenopausal African American women, and a suggestion that increased parity, younger age at first term pregnancy, shorter duration of breast feeding, and elevated hip-to-waist ratio might be particular risk factors. In recent years, a greater understanding of the biology of this disease has led to the development of numerous and varied therapeutic approaches. Neoadjuvant trials using conventional cytotoxic agents such as cisplatin have demonstrated TNBC to be a relatively chemosensitive disease. Drugs developed to inhibit the angiogenic process may be particularly effective in TNBC. The molecular chaperone heat shock protein (HSP90) is required for the conformational maturation and stability of a variety of proteins in multiple pathways, such as epidermal growth factor receptor (EGFR), AKT, Raf, cdk4, etc. Therefore, an HSP90 inhibitor may show therapeutic benefit in TNBC by targeting multiple pathways. In terms of therapy, an increasingly rational drug development effort has resulted in agents against new molecular targets that are active against P. Kaur ( ) Assistant Professor,

show abstract

“…The poor prognosis of Black women with breast cancer in the United States is a case in point [1]. Despite the low frequency of breast cancer in Black women overall, Black women have a higher mortality compared to White women and other ethnic groups.…”

Section: Introductionmentioning

confidence: 97%